Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (19929)
All Articles published online
|
Publishing Process of This Article
|
Jan 14, 2018 (publication date) through Nov 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Tølbøl KS, Kristiansen MN, Hansen HH, Veidal SS, Rigbolt KT, Gillum MP, Jelsing J, Vrang N, Feigh M. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J Gastroenterol 2018; 24(2): 179-194 [PMID: 29375204 DOI: 10.3748/wjg.v24.i2.179] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v24/i2/179.htm |
| Number | Citing Articles |
| 1 |
Moritz Helmstädter, Jurema Schmidt, Astrid Kaiser, Lilia Weizel, Ewgenij Proschak, Daniel Merk. Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR/sEH Modulation in NASH in Diet-Induced Obese Mice. ACS Pharmacology & Translational Science 2021; 4(2): 966 doi: 10.1021/acsptsci.1c00041
|
| 2 |
Mathias B. Møllerhøj, Sanne S. Veidal, Kirstine Tølbøl Thrane, Denise Oró, Agnete Overgaard, Casper Gravesen Salinas, Martin Rønn Madsen, Larissa Pfisterer, Mogens Vyberg, Eric Simon, Andre Broermann, Niels Vrang, Jacob Jelsing, Michael Feigh, Henrik H. Hansen. Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet‐induced obese and biopsy‐confirmed mouse model of NASH. Clinical and Translational Science 2022; 15(5): 1167 doi: 10.1111/cts.13235
|
| 3 |
Geurt Stokman, Anita M. van den Hoek, Ditte Denker Thorbekk, Elsbet J. Pieterman, Sanne Skovgård Veidal, Brittany Basta, Marta Iruarrizaga‐Lejarreta, José W. van der Hoorn, Lars Verschuren, Jimmy F. P. Berbée, Patrick C. N. Rensen, Tore Skjæret, Cristina Alonso, Michael Feigh, John J. P. Kastelein, Scott L. Friedman, Hans M. G. Princen, David A. Fraser. Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative. Liver International 2020; 40(11): 2860 doi: 10.1111/liv.14643
|
| 4 |
Thibaut Duparc, François Briand, Charlotte Trenteseaux, Jules Merian, Guillaume Combes, Souad Najib, Thierry Sulpice, Laurent O. Martinez. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis. American Journal of Physiology-Gastrointestinal and Liver Physiology 2019; 317(4): G508 doi: 10.1152/ajpgi.00139.2019
|
| 5 |
Hieu Huy Phung, Chang Hoon Lee. Mouse models of nonalcoholic steatohepatitis and their application to new drug development. Archives of Pharmacal Research 2022; 45(11): 761 doi: 10.1007/s12272-022-01410-5
|
| 6 |
Jonathan D. Roth, Sanne S. Veidal, Louise K. D. Fensholdt, Kristoffer T. G. Rigbolt, Romeo Papazyan, Jens Christian Nielsen, Michael Feigh, Niels Vrang, Mark Young, Jacob Jelsing, Luciano Adorini, Henrik H. Hansen. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-45178-z
|
| 7 |
Kristiaan Wouters, Alessia S. Cento, Katrien H. Gaens, Margee Teunissen, Jean L. J. M. Scheijen, Federica Barutta, Fausto Chiazza, Debora Collotta, Manuela Aragno, Gabriella Gruden, Massimo Collino, Casper G. Schalkwijk, Raffaella Mastrocola. Deletion of RAGE fails to prevent hepatosteatosis in obese mice due to impairment of other AGEs receptors and detoxifying systems. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-96859-7
|
| 8 |
Aimo Kannt, Andreas Nygaard Madsen, Claire Kammermeier, Ralf Elvert, Tim Klöckener, Martin Bossart, Torsten Haack, Andreas Evers, Katrin Lorenz, Wolfgang Hennerici, Corinne Rocher, Zsolt Böcskei, Jean‐Claude Guillemot, Vincent Mikol, Francois Pattou, Bart Staels, Michael Wagner. Incretin combination therapy for the treatment of non‐alcoholic steatohepatitis. Diabetes, Obesity and Metabolism 2020; 22(8): 1328 doi: 10.1111/dom.14035
|
| 9 |
Mette Simone Aae Madsen, Jacob Bak Holm, Albert Pallejà, Pernille Wismann, Katrine Fabricius, Kristoffer Rigbolt, Martin Mikkelsen, Morten Sommer, Jacob Jelsing, Henrik Bjørn Nielsen, Niels Vrang, Henrik H. Hansen. Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-52103-x
|
| 10 |
Marcos Antonio Ferreira, Hatylas Azevedo, Alessandra Mascarello, Natanael Dante Segretti, Elisa Russo, Valter Russo, Cristiano Ruch Werneck Guimarães. Discovery of ACH-000143: A Novel Potent and Peripherally Preferred Melatonin Receptor Agonist that Reduces Liver Triglycerides and Steatosis in Diet-Induced Obese Rats. Journal of Medicinal Chemistry 2021; 64(4): 1904 doi: 10.1021/acs.jmedchem.0c00627
|
| 11 |
Ludovico Abenavoli, Tetyana Falalyeyeva, Luigi Boccuto, Olena Tsyryuk, Nazarii Kobyliak. Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease. Pharmaceuticals 2018; 11(4): 104 doi: 10.3390/ph11040104
|
| 12 |
Mirai Yamazaki, Misaki Okito, Akio Harada, Keisuke Miyake, Takashi Tamiya, Takehiro Nakamura. d‐Allulose Supplementation Prevents Diet‐Induced Hepatic Lipid Accumulation via miR‐130‐Mediated Regulation in C57BL/6 Mice. Molecular Nutrition & Food Research 2023; 67(3) doi: 10.1002/mnfr.202200748
|
| 13 |
Arun J. Sanyal, Vlad Ratziu, Rohit Loomba, Quentin M. Anstee, Kris V. Kowdley, Mary E. Rinella, Muhammad Y. Sheikh, James F. Trotter, Whitfield Knapple, Eric J. Lawitz, Manal F. Abdelmalek, Philip N. Newsome, Jérôme Boursier, Philippe Mathurin, Jean-François Dufour, M. Michelle Berrey, Steven J. Shiff, Sangeeta Sawhney, Thomas Capozza, Rina Leyva, Stephen A. Harrison, Zobair M. Younossi. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis. Journal of Hepatology 2023; 79(5): 1110 doi: 10.1016/j.jhep.2023.07.014
|
| 14 |
Hang Zhang, Xuan Dong, Lei Zhu, Fu-Shan Tang. Elafibranor: A promising treatment for alcoholic liver disease, metabolic-associated fatty liver disease, and cholestatic liver disease. World Journal of Gastroenterology 2024; 30(40): 4393-4398 doi: 10.3748/wjg.v30.i40.4393
|
| 15 |
Thomas Monfeuga, Jenny Norlin, Anne Bugge, Elisabeth D. Gaalsgaard, Cesar A. Prada-Medina, Markus Latta, Sanne S. Veidal, Pia S. Petersen, Michael Feigh, Dorte Holst. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients. Molecular Metabolism 2024; 79: 101850 doi: 10.1016/j.molmet.2023.101850
|
| 16 |
Danny Orabi, Nathan A. Berger, J. Mark Brown. Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention. Cancers 2021; 13(14): 3473 doi: 10.3390/cancers13143473
|
| 17 |
Sarah Lechner, Matthew Yee, Berkeley N. Limketkai, Edward A. Pham. Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction. Digestive Diseases and Sciences 2020; 65(3): 897 doi: 10.1007/s10620-020-06100-0
|
| 18 |
Mathias Flensted-Jensen, Denise Oró, Emma A. Rørbeck, Chen Zhang, Martin Rønn Madsen, Andreas Nygaard Madsen, Jenny Norlin, Michael Feigh, Steen Larsen, Henrik H. Hansen. Dietary intervention reverses molecular markers of hepatocellular senescence in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH. BMC Gastroenterology 2024; 24(1) doi: 10.1186/s12876-024-03141-x
|
| 19 |
Kang Wang, Yuecan Zhang, Guangji Wang, Haiping Hao, Hong Wang. FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid. Medicinal Research Reviews 2024; 44(2): 568 doi: 10.1002/med.21991
|
| 20 |
Hyunmi Kim, Da Som Lee, Tae Hyeon An, Hyun-Ju Park, Won Kon Kim, Kwang-Hee Bae, Kyoung-Jin Oh. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. International Journal of Molecular Sciences 2021; 22(9): 4495 doi: 10.3390/ijms22094495
|
| 21 |
Elise Anne van Os, Laura Cools, Nathalie Eysackers, Karolina Szafranska, Ayla Smout, Stefaan Verhulst, Hendrik Reynaert, Peter McCourt, Inge Mannaerts, Leo A. van Grunsven. Modelling fatty liver disease with mouse liver-derived multicellular spheroids. Biomaterials 2022; 290: 121817 doi: 10.1016/j.biomaterials.2022.121817
|
| 22 |
Xiaoxi Li, Wenwen Zhao, Meng Xiao, Lan Yu, Qijun Chen, Xiaolu Hu, Yimeng Zhao, Lijuan Xiong, Xiaoqing Chen, Xing Wang, Yinying Ba, Qiang Guo, Xia Wu. Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice. Journal of Ethnopharmacology 2022; 294: 115333 doi: 10.1016/j.jep.2022.115333
|
| 23 |
Jose Corbalan, Pranavi Jagadeesan, Karla K. Frietze, Rulaiha Taylor, Grace L. Gao, Grant Gallagher, Joseph T. Nickels. Humanized Monoacylglycerol Acyltransferase 2 Mice Develop Metabolic Dysfunction-Associated Steatohepatitis. Journal of Lipid Research 2024; : 100695 doi: 10.1016/j.jlr.2024.100695
|
| 24 |
Daniel Ferguson, Brian N. Finck. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nature Reviews Endocrinology 2021; 17(8): 484 doi: 10.1038/s41574-021-00507-z
|
| 25 |
Shuangjie Yang, Deshuai Yu, Junjie Liu, Yanfang Qiao, Shuxiao Gu, Ran Yang, Xinlou Chai, Wei Wang. Global publication trends and research hotspots of the gut-liver axis in NAFLD: A bibliometric analysis. Frontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1121540
|
| 26 |
Jose Cordoba-Chacon. Loss of Hepatocyte-Specific PPARγ Expression Ameliorates Early Events of Steatohepatitis in Mice Fed the Methionine and Choline-Deficient Diet. PPAR Research 2020; 2020: 1 doi: 10.1155/2020/9735083
|
| 27 |
Nikolaos Perakakis, Aditya Joshi, Natia Peradze, Konstantinos Stefanakis, Georgia Li, Michael Feigh, Sanne Skovgard Veidal, Glenn Rosen, Michael Fleming, Christos S. Mantzoros. The Selective Peroxisome Proliferator‐Activated Receptor Gamma Modulator CHS‐131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis. Hepatology Communications 2020; 4(9): 1302 doi: 10.1002/hep4.1558
|
| 28 |
Lucia Sessa, Simona Concilio, Jesús Fominaya, Daniela Eletto, Stefano Piotto, Xavier Busquets. A new serotonin 2A receptor antagonist with potential benefits in Non-Alcoholic Fatty Liver Disease. Life Sciences 2023; 314: 121315 doi: 10.1016/j.lfs.2022.121315
|
| 29 |
Qi Su, Sun Y. Kim, Funmi Adewale, Ye Zhou, Christina Aldler, Min Ni, Yi Wei, Michael E. Burczynski, Gurinder S. Atwal, Mark W. Sleeman, Andrew J. Murphy, Yurong Xin, Xiping Cheng. Single-cell RNA transcriptome landscape of hepatocytes and non-parenchymal cells in healthy and NAFLD mouse liver. iScience 2021; 24(11): 103233 doi: 10.1016/j.isci.2021.103233
|
| 30 |
Martin Bossart, Michael Wagner, Ralf Elvert, Andreas Evers, Thomas Hübschle, Tim Kloeckener, Katrin Lorenz, Christine Moessinger, Olof Eriksson, Irina Velikyan, Stefan Pierrou, Lars Johansson, Gabriele Dietert, Yasmin Dietz-Baum, Thomas Kissner, Irene Nowotny, Christine Einig, Christelle Jan, Faiza Rharbaoui, Johann Gassenhuber, Hans-Peter Prochnow, Inoncent Agueusop, Niels Porksen, William B. Smith, Almut Nitsche, Anish Konkar. Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. Cell Metabolism 2022; 34(1): 59 doi: 10.1016/j.cmet.2021.12.005
|
| 31 |
Emma Rose McGlone, David C.D. Hope, Iona Davies, Marian Dore, Rob Goldin, Ben Jones, Zhigang Liu, Jia V. Li, Panagiotis A. Vorkas, Bernard Khoo, David Carling, James Minnion, Stephen R. Bloom, Tricia M-M. Tan. Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity. Biomedicine & Pharmacotherapy 2024; 176: 116888 doi: 10.1016/j.biopha.2024.116888
|
| 32 |
Joseph Yi Zhou, Anil Poudel, Ryan Welchko, Naveen Mekala, Prashanth Chandramani-Shivalingappa, Mariana Georgeta Rosca, Lixin Li. Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways. European Journal of Pharmacology 2019; 861: 172594 doi: 10.1016/j.ejphar.2019.172594
|
| 33 |
Archana Vijayakumar, Ayse Okesli‐Armlovich, Ting Wang, Isabel Olson, Minji Seung, Saritha Kusam, David Hollenback, Sangeetha Mahadevan, Bruno Marchand, Maria Toteva, David G. Breckenridge, James L. Trevaskis, Jamie Bates. Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis. Hepatology Communications 2022; 6(9): 2298 doi: 10.1002/hep4.2011
|
| 34 |
Pankaj Aggarwal, Tamneet Singh, Naim Alkhouri. Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the Disease at the Metabolic Root. Current Hepatology Reports 2020; 19(3): 302 doi: 10.1007/s11901-020-00533-x
|
| 35 |
Malte Hasle Nielsen, Matthew P. Gillum, Niels Vrang, Jacob Jelsing, Henrik H. Hansen, Michael Feigh, Denise Oró. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis. American Journal of Physiology-Gastrointestinal and Liver Physiology 2023; 324(5): G378 doi: 10.1152/ajpgi.00157.2022
|
| 36 |
Henrik H. Hansen, Susanne Pors, Maja W. Andersen, Mogens Vyberg, Jacob Nøhr-Meldgaard, Malte Hasle Nielsen, Denise Oró, Martin Rønn Madsen, Monika Lewinska, Mathias B. Møllerhøj, Andreas Nygaard Madsen, Michael Feigh. Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-50328-5
|
| 37 |
David H Ipsen, Jens Lykkesfeldt, Pernille Tveden-Nyborg. Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?. Advances in Nutrition 2020; 11(6): 1696 doi: 10.1093/advances/nmaa081
|
| 38 |
Emilia Gore, Emilia Bigaeva, Anouk Oldenburger, Yvette J. M. Jansen, Detlef Schuppan, Miriam Boersema, Jörg F. Rippmann, Andre Broermann, Peter Olinga. Investigating fibrosis and inflammation in an ex vivo NASH murine model. American Journal of Physiology-Gastrointestinal and Liver Physiology 2020; 318(2): G336 doi: 10.1152/ajpgi.00209.2019
|
| 39 |
Joel Yeh Siang Chen, Damien Chua, Carissa Odelia Lim, Wan Xi Ho, Nguan Soon Tan. Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials. International Journal of Molecular Sciences 2022; 24(1): 158 doi: 10.3390/ijms24010158
|
| 40 |
Iris Pinheiro. A Comprehensive Guide to Nonalcoholic Fatty Liver Disease [Working Title]. 2024; doi: 10.5772/intechopen.1007741
|
| 41 |
Daniel Lindén, Andrea Ahnmark, Piero Pingitore, Ester Ciociola, Ingela Ahlstedt, Anne-Christine Andréasson, Kavitha Sasidharan, Katja Madeyski-Bengtson, Magdalena Zurek, Rosellina M. Mancina, Anna Lindblom, Mikael Bjursell, Gerhard Böttcher, Marcus Ståhlman, Mohammad Bohlooly-Y, William G. Haynes, Björn Carlsson, Mark Graham, Richard Lee, Sue Murray, Luca Valenti, Sanjay Bhanot, Peter Åkerblad, Stefano Romeo. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice. Molecular Metabolism 2019; 22: 49 doi: 10.1016/j.molmet.2019.01.013
|
| 42 |
Adel Hammoutene, Samira Laouirem, Miguel Albuquerque, Nathalie Colnot, Angélique Brzustowski, Dominique Valla, Nicolas Provost, Philippe Delerive, Valérie Paradis. A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease. JHEP Reports 2023; 5(10): 100845 doi: 10.1016/j.jhepr.2023.100845
|
| 43 |
Vasiliki Venetsanaki, Zacharoula Karabouta, Stergios A. Polyzos. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis. European Journal of Pharmacology 2019; 863: 172661 doi: 10.1016/j.ejphar.2019.172661
|
| 44 |
Martine C. Morrison, Lars Verschuren, Kanita Salic, Joanne Verheij, Aswin Menke, Peter Y. Wielinga, Marta Iruarrizaga‐Lejarreta, Laurent Gole, Wei‐Miao Yu, Scott Turner, Martien P.M. Caspers, Ibon Martínez‐Arranz, Elsbet Pieterman, Reinout Stoop, Arianne van Koppen, Anita M. van den Hoek, José M. Mato, Roeland Hanemaaijer, Cristina Alonso, Robert Kleemann. Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr‐/‐.Leiden Mice. Hepatology Communications 2018; 2(12): 1513 doi: 10.1002/hep4.1270
|
| 45 |
Kirstine S. Tølbøl, Birgit Stierstorfer, Jörg F. Rippmann, Sanne S. Veidal, Kristoffer T. G. Rigbolt, Tanja Schönberger, Matthew P. Gillum, Henrik H. Hansen, Niels Vrang, Jacob Jelsing, Michael Feigh, Andre Broermann. Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis. Digestive Diseases and Sciences 2019; 64(5): 1238 doi: 10.1007/s10620-018-5395-7
|
| 46 |
Eun Jeoung Lee, Yun Kim, Ji Eun Kim, Eileen Laurel Yoon, Sung Ryol Lee, Dae Won Jun. ALS-L1023 from Melissa officinalis Alleviates Liver Fibrosis in a Non-Alcoholic Fatty Liver Disease Model. Life 2022; 13(1): 100 doi: 10.3390/life13010100
|
| 47 |
Guodong Zhang, Xiaoli Wang, Tzu-Yang Chung, Weiwei Ye, Lauren Hodge, Likun Zhang, Keefe Chng, Yong-Fu Xiao, Yixin Jim Wang. Carbon tetrachloride (CCl4) accelerated development of non-alcoholic fatty liver disease (NAFLD)/steatohepatitis (NASH) in MS-NASH mice fed western diet supplemented with fructose (WDF). BMC Gastroenterology 2020; 20(1) doi: 10.1186/s12876-020-01467-w
|
| 48 |
Anne Fougerat, Alexandra Montagner, Nicolas Loiseau, Hervé Guillou, Walter Wahli. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. Cells 2020; 9(7): 1638 doi: 10.3390/cells9071638
|
| 49 |
Michael Karin, Ju Youn Kim. MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives. Molecular Oncology 2024; doi: 10.1002/1878-0261.13685
|
| 50 |
Yiming Ni, Mengna Lu, Yuan Xu, Qixue Wang, Xinyi Gu, Ying Li, Tongxi Zhuang, Chenyi Xia, Ting Zhang, Xiao-jun Gou, Mingmei Zhou. The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease. Frontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.908011
|
| 51 |
John J. Nestor, David Parkes, Michael Feigh, John J. Suschak, M. Scott Harris. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-10577-2
|
| 52 |
Chara Tsiampali, Ilias D. Vachliotis, Antonis Goulas, Stergios A. Polyzos. Animal studies on glucagon-like peptide-1 receptor agonists and related polyagonists in nonalcoholic fatty liver disease. Hormones 2024; 23(4): 611 doi: 10.1007/s42000-024-00541-2
|
| 53 |
Keishi Kisoh, Go Sugahara, Yuko Ogawa, Suzue Furukawa, Yuji Ishida, Takeshi Okanoue, Michinori Kohara, Chise Tateno. Estimating Drug Efficacy with a Diet-Induced NASH Model in Chimeric Mice with Humanized Livers. Biomedicines 2021; 9(11): 1647 doi: 10.3390/biomedicines9111647
|
| 54 |
Phil Pickford, Maria Lucey, Roxana-Maria Rujan, Emma Rose McGlone, Stavroula Bitsi, Fiona B. Ashford, Ivan R. Corrêa, David J. Hodson, Alejandra Tomas, Giuseppe Deganutti, Christopher A. Reynolds, Bryn M. Owen, Tricia M. Tan, James Minnion, Ben Jones, Stephen R. Bloom. Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist. Molecular Metabolism 2021; 51: 101242 doi: 10.1016/j.molmet.2021.101242
|
| 55 |
Seung-Ho Lee, Hansu Park, Eun-Kyoung Yang, Bo Ram Lee, Il-Hoon Jung, Tae-Hyoung Kim, Moon Jung Goo, Yuna Chae, Mi-Kyung Kim. GPR119 activation by DA-1241 alleviates hepatic and systemic inflammation in MASH mice through inhibition of NFκB signaling. Biomedicine & Pharmacotherapy 2023; 166: 115345 doi: 10.1016/j.biopha.2023.115345
|
| 56 |
Seogsong Jeong, Woo-Young Shin, Yun Hwan Oh. Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma. Frontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1150360
|
| 57 |
Samuel J. Daniels, Diana J. Leeming, Sönke Detlefsen, Maria F. Bruun, Sara T. Hjuler, Kim Henriksen, Peter Hein, Morten A. Karsdal, Sarah Brockbank, Simon Cruwys. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis – Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue. Biomedicine & Pharmacotherapy 2019; 111: 926 doi: 10.1016/j.biopha.2018.12.130
|
| 58 |
Yvonne Oligschlaeger, Ronit Shiri-Sverdlov. NAFLD Preclinical Models: More than a Handful, Less of a Concern?. Biomedicines 2020; 8(2): 28 doi: 10.3390/biomedicines8020028
|
| 59 |
Julian M Yabut, Daniel J Drucker. Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease. Endocrine Reviews 2023; 44(1): 14 doi: 10.1210/endrev/bnac018
|
| 60 |
Shotaro Kamata, Akihiro Honda, Isao Ishii. Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease. Biomolecules 2023; 13(8): 1264 doi: 10.3390/biom13081264
|
| 61 |
Vanessa Touceda, Florencia Fontana Estevez, Leonardo Cacciagiú, Paola Finocchietto, Romina Bustos, Agustina Vidal, Gabriela Berg, Celina Morales, Germán E. González, Veronica Miksztowicz. Liraglutide improves adipose tissue remodeling and mitochondrial dynamics in a visceral obesity model induced by a high-fat diet. Current Research in Pharmacology and Drug Discovery 2024; 6: 100185 doi: 10.1016/j.crphar.2024.100185
|
| 62 |
Maria N. B. Kristiansen, Sanne S. Veidal, Christina Christoffersen, Jacob Jelsing, Kristoffer T. G. Rigbolt. Molecular Characterization of Microvesicular and Macrovesicular Steatosis Shows Widespread Differences in Metabolic Pathways. Lipids 2019; 54(1): 109 doi: 10.1002/lipd.12121
|
| 63 |
Marion Régnier, Thaïs Carbinatti, Lucia Parlati, Fadila Benhamed, Catherine Postic. The role of ChREBP in carbohydrate sensing and NAFLD development. Nature Reviews Endocrinology 2023; 19(6): 336 doi: 10.1038/s41574-023-00809-4
|
| 64 |
Laurène Meyniel-Schicklin, Jérôme Amaudrut, Pierre Mallinjoud, Fabrice Guillier, Philippe E. Mangeot, Laetitia Lines, Anne Aublin-Gex, Caroline Scholtes, Claire Punginelli, Stéphane Joly, Florence Vasseur, Evelyne Manet, Henri Gruffat, Thomas Henry, Farès Halitim, Jean-Laurent Paparin, Peter Machin, Raphaël Darteil, Diane Sampson, Ivan Mikaelian, Lydie Lane, Vincent Navratil, Marie-Pierre Golinelli-Cohen, Fabiola Terzi, Patrice André, Vincent Lotteau, Jacky Vonderscher, Eric C. Meldrum, Benoit de Chassey. Viruses traverse the human proteome through peptide interfaces that can be biomimetically leveraged for drug discovery. Proceedings of the National Academy of Sciences 2024; 121(5) doi: 10.1073/pnas.2308776121
|
| 65 |
Qian-Nan Di, Wei-Xin Cao, Run Xu, Lingeng Lu, Qian Xu, Xiao-Bin Wang. Chronic low-dose exposure of nonylphenol alters energy homeostasis in the reproductive system of female rats. Toxicology and Applied Pharmacology 2018; 348: 67 doi: 10.1016/j.taap.2018.04.007
|
| 66 |
Sanja Stojsavljevic-Shapeski, Marko Duvnjak, Lucija Virovic-Jukic, Davor Hrabar, Lea Smircic Duvnjak. New Drugs on the Block—Emerging Treatments for Nonalcoholic Steatohepatitis. Journal of Clinical and Translational Hepatology 2020; 0(000): 1 doi: 10.14218/JCTH.2020.00057
|
| 67 |
Pascale Gluais‐Dagorn, Marc Foretz, Gregory R. Steinberg, Battsetseg Batchuluun, Anna Zawistowska‐Deniziak, Joost M. Lambooij, Bruno Guigas, David Carling, Pierre‐Axel Monternier, David E. Moller, Sebastien Bolze, Sophie Hallakou‐Bozec. Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis. Hepatology Communications 2022; 6(1): 101 doi: 10.1002/hep4.1799
|
| 68 |
Eloy D. Hernandez, Lianxing Zheng, Young Kim, Bin Fang, Bo Liu, Reginald A. Valdez, William F. Dietrich, Paul V. Rucker, Donatella Chianelli, James Schmeits, Dingjiu Bao, Jocelyn Zoll, Claire Dubois, Glenn C. Federe, Lihao Chen, Sean B. Joseph, Lloyd B. Klickstein, John Walker, Valentina Molteni, Peter McNamara, Shelly Meeusen, David C. Tully, Michael K. Badman, Jie Xu, Bryan Laffitte. Tropifexor‐Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents. Hepatology Communications 2019; 3(8): 1085 doi: 10.1002/hep4.1368
|
| 69 |
Anita M. van den Hoek, Lars Verschuren, Nicole Worms, Anita van Nieuwkoop, Christa de Ruiter, Joline Attema, Aswin L. Menke, Martien P. M. Caspers, Sridhar Radhakrishnan, Kanita Salic, Robert Kleemann. A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology. Cells 2020; 9(9): 2014 doi: 10.3390/cells9092014
|
| 70 |
L. Kořínková, V. Pražienková, L. Černá, A. Karnošová, B. Železná, J. Kuneš, Lenka Maletínská. Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides. Frontiers in Endocrinology 2020; 11 doi: 10.3389/fendo.2020.597583
|
| 71 |
Henrik H. Hansen, Helene M. Ægidius, Denise Oró, Simon S. Evers, Sara Heebøll, Peter Lykke Eriksen, Karen Louise Thomsen, Anja Bengtsson, Sanne S. Veidal, Michel Feigh, Malte P. Suppli, Filip K. Knop, Henning Grønbæk, Diego Miranda, James L. Trevaskis, Niels Vrang, Jacob Jelsing, Kristoffer T. G. Rigbolt. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterology 2020; 20(1) doi: 10.1186/s12876-020-01356-2
|
| 72 |
Chara Tsiampali, Paraskevi Papaioannidou, Antonis Goulas, Stergios A. Polyzos. The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease. Expert Review of Clinical Pharmacology 2023; 16(11): 1063 doi: 10.1080/17512433.2023.2274536
|
| 73 |
Victoria S. Jensen, Pernille Tveden-Nyborg, Christina Zacho-Rasmussen, Michelle L. Quaade, David H. Ipsen, Henning Hvid, Christian Fledelius, Erik M. Wulff, Jens Lykkesfeldt. Variation in diagnostic NAFLD/NASH read-outs in paired liver samples from rodent models. Journal of Pharmacological and Toxicological Methods 2020; 101: 106651 doi: 10.1016/j.vascn.2019.106651
|
| 74 |
Omar Hegazi, Samer Alalalmeh, Moyad Shahwan, Ammar Jairoun, Mansour Alourfi, Ghfran Bokhari, Abdullah Alkhattabi, Saeed Alsharif, Mohannad Aljehani, Abdulmalik Alsabban, Mohammad Almtrafi, Ysear Zakri, Abdullah AlMahmoud, Khalid Alghamdi, Ahmed Ashour, Nasser Alorfi. Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis. Diabetes, Metabolic Syndrome and Obesity 2024; : 545 doi: 10.2147/DMSO.S448476
|
| 75 |
Cristina Zivko, Finja Witt, Andreas Koeberle, Gregor Fuhrmann, Paola Luciani. Formulating elafibranor and obeticholic acid with phospholipids decreases drug-induced association of SPARC to extracellular vesicles from LX-2 human hepatic stellate cells. European Journal of Pharmaceutics and Biopharmaceutics 2023; 182: 32 doi: 10.1016/j.ejpb.2022.11.025
|
| 76 |
Yun-Jung Choi, Jeff D. Johnson, Jin-Ju Lee, Jiangao Song, Marcy Matthews, Marc K. Hellerstein, Charles A. McWherter. Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis. American Journal of Physiology-Gastrointestinal and Liver Physiology 2024; 326(2): G120 doi: 10.1152/ajpgi.00158.2023
|
| 77 |
Olufunto O. Badmus, Sarah A. Hillhouse, Christopher D. Anderson, Terry D. Hinds, David E. Stec. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways. Clinical Science 2022; 136(18): 1347 doi: 10.1042/CS20220572
|
| 78 |
Lin Zhang, Xiaojuan Wu, Xinyue Li, Xiaona Chang, Xiaoyu Ding, Qiu Wang, Tao Jiang, Guang Wang, Jia Liu. Longitudinal changes in serum adropin levels and liver fat content during liraglutide treatment in newly diagnosed patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease. Acta Diabetologica 2023; 60(7): 971 doi: 10.1007/s00592-023-02082-3
|
| 79 |
Yeon Ji Chae, Dae Won Jun, Waqar Khalid Saeed, Hyeon Tae Kang, Ju Hee Oh, Seung Min Lee, Kiseok Jang. Feasibility and Stability of Liver Biopsy before Treatment for Preclinical Nonalcoholic Fatty Liver Studies. Journal of Korean Medical Science 2019; 34(2) doi: 10.3346/jkms.2019.34.e14
|
| 80 |
Devaraj Ezhilarasan. Unraveling the pathophysiologic role of galectin‐3 in chronically injured liver. Journal of Cellular Physiology 2023; 238(4): 673 doi: 10.1002/jcp.30956
|
| 81 |
Henrik H. Hansen, Gitte Hansen, Thomas Secher, Michael Feigh, Sanne S. Veidal, Keld Fosgerau, Jacob Jelsing, Niels Vrang. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. 2019; : 369 doi: 10.1007/978-3-030-11748-1_14
|
| 82 |
Davide Povero, Milos Lazic, Christopher McBride, Geza Ambrus-Aikelin, Ryan Stansfield, Casey D. Johnson, Angelina M. Santini, Rama F. Pranadinata, Matthew D. McGeough, Jeffrey A. Stafford, Hal M. Hoffman, Ariel E. Feldstein, James M. Veal, Gretchen Bain. Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis. Journal of Pharmacology and Experimental Therapeutics 2023; 386(2): 242 doi: 10.1124/jpet.123.001639
|
| 83 |
Tieshan Teng, Shuai Qiu, Yiming Zhao, Siyuan Zhao, Dequan Sun, Lingzhu Hou, Yihang Li, Ke Zhou, Xixi Yu, Changyong Yang, Yanzhang Li. Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences 2022; 23(14): 7841 doi: 10.3390/ijms23147841
|
| 84 |
François Briand, Christophe Heymes, Lucile Bonada, Thibault Angles, Julie Charpentier, Maxime Branchereau, Emmanuel Brousseau, Marjolaine Quinsat, Nicolas Fazilleau, Rémy Burcelin, Thierry Sulpice. A 3‐week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death. Clinical and Translational Science 2020; 13(3): 529 doi: 10.1111/cts.12735
|
| 85 |
Suling Huang, Yanwei Wu, Zhuohui Zhao, Bing Wu, Kai Sun, Haoyu Wang, Li Qin, Fang Bai, Ying Leng, Wei Tang. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage. Metabolism 2021; 120: 154797 doi: 10.1016/j.metabol.2021.154797
|
| 86 |
Pascal Heitel, Giuseppe Faudone, Moritz Helmstädter, Jurema Schmidt, Astrid Kaiser, Amelie Tjaden, Martin Schröder, Susanne Müller, Simone Schierle, Julius Pollinger, Daniel Merk. A triple farnesoid X receptor and peroxisome proliferator-activated receptor α/δ activator reverses hepatic fibrosis in diet-induced NASH in mice. Communications Chemistry 2020; 3(1) doi: 10.1038/s42004-020-00411-z
|
| 87 |
Sofie M. Bendixen, Peter R. Jakobsgaard, Daniel Hansen, Kamilla H. Hejn, Mike K. Terkelsen, Frederik A. Bjerre, Annemette P. Thulesen, Niels G. Eriksen, Philip Hallenborg, Yana Geng, Trine V. Dam, Frederik T. Larsen, Charlotte W. Wernberg, Janusa Vijayathurai, Emma A.H. Scott, Ann-Britt Marcher, Sönke Detlefsen, Lars Grøntved, Henrik Dimke, Rebecca Berdeaux, Thomas Q. de Aguiar Vallim, Peter Olinga, Mette M. Lauridsen, Aleksander Krag, Blagoy Blagoev, Kim Ravnskjaer. Single cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling module. Journal of Hepatology 2024; 80(3): 467 doi: 10.1016/j.jhep.2023.11.001
|
| 88 |
Ines C.M. Simoes, Justyna Janikiewicz, Judith Bauer, Agnieszka Karkucinska-Wieckowska, Piotr Kalinowski, Agnieszka Dobrzyń, Andrzej Wolski, Maciej Pronicki, Krzysztof Zieniewicz, Paweł Dobrzyń, Marcin Krawczyk, Hans Zischka, Mariusz R. Wieckowski, Yaiza Potes. Fat and Sugar—A Dangerous Duet. A Comparative Review on Metabolic Remodeling in Rodent Models of Nonalcoholic Fatty Liver Disease. Nutrients 2019; 11(12): 2871 doi: 10.3390/nu11122871
|
| 89 |
Zichen Luo, Wei Zhou, Tong Xie, Weichen Xu, Chen Shi, Zihan Xiao, Yu Si, Yan Ma, Qingling Ren, Liuqing Di, Jinjun Shan. The role of botanical triterpenoids and steroids in bile acid metabolism, transport, and signaling: Pharmacological and toxicological implications. Acta Pharmaceutica Sinica B 2024; 14(8): 3385 doi: 10.1016/j.apsb.2024.04.027
|
| 90 |
Anita M. van den Hoek, Lars Verschuren, Martien P. M. Caspers, Nicole Worms, Aswin L. Menke, Hans M. G. Princen. Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-83974-8
|
| 91 |
Maria Lucey, Philip Pickford, Stavroula Bitsi, James Minnion, Jan Ungewiss, Katja Schoeneberg, Guy A. Rutter, Stephen R. Bloom, Alejandra Tomas, Ben Jones. Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists. Molecular Metabolism 2020; 37: 100991 doi: 10.1016/j.molmet.2020.100991
|
| 92 |
Bader Zarrouki, Jeremie Boucher. Kupffer Cells. Methods in Molecular Biology 2020; 2164: 121 doi: 10.1007/978-1-0716-0704-6_13
|
| 93 |
Suraphan Panyod, Wei-Kai Wu, Meng-Yun Hu, Huai-Syuan Huang, Rou-An Chen, Yi-Hsun Chen, Ting-Chin David Shen, Chi-Tang Ho, Chun-Jen Liu, Hsiao-Li Chuang, Chi-Chang Huang, Ming-Shiang Wu, Lee-Yan Sheen, Wei-Hua Chen. Healthy diet intervention reverses the progression of NASH through gut microbiota modulation. Microbiology Spectrum 2024; 12(1) doi: 10.1128/spectrum.01868-23
|
| 94 |
Wen-Cong Li, Su-Xian Zhao, Wei-Guang Ren, Yu-Guo Zhang, Rong-Qi Wang, Ling-Bo Kong, Qing-Shan Zhang, Yue-Min Nan. Co‑administration of obeticholic acid and simvastatin protects against high‑fat diet‑induced non‑alcoholic steatohepatitis in mice. Experimental and Therapeutic Medicine 2021; 22(2) doi: 10.3892/etm.2021.10262
|
| 95 |
Piero Pingitore, Kavitha Sasidharan, Matias Ekstrand, Sebastian Prill, Daniel Lindén, Stefano Romeo. Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis. International Journal of Molecular Sciences 2019; 20(7): 1629 doi: 10.3390/ijms20071629
|
| 96 |
Michelle L Boland, Denise Oró, Kirstine S Tølbøl, Sebastian T Thrane, Jens Christian Nielsen, Taylor S Cohen, David E Tabor, Fiona Fernandes, Andrey Tovchigrechko, Sanne S Veidal, Paul Warrener, Bret R Sellman, Jacob Jelsing, Michael Feigh, Niels Vrang, James L Trevaskis, Henrik H Hansen. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source. World Journal of Gastroenterology 2019; 25(33): 4904-4920 doi: 10.3748/wjg.v25.i33.4904
|
| 97 |
Maria Nicoline Baandrup Kristiansen, Sanne Skovgård Veidal, Christina Christoffersen, Michael Feigh, Niels Vrang, Jonathan David Roth, Mary Erickson, Luciano Adorini, Jacob Jelsing. Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH. BMC Gastroenterology 2019; 19(1) doi: 10.1186/s12876-019-1149-z
|
| 98 |
Monica Gomaraschi, Anna Ludovica Fracanzani, Paola Dongiovanni, Chiara Pavanello, Eleonora Giorgio, Lorenzo Da Dalt, Giuseppe Danilo Norata, Laura Calabresi, Dario Consonni, Rosa Lombardi, Adriana Branchi, Silvia Fargion. Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: Evidence in NAFLD patients and cell cultures. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2019; 1864(12): 158523 doi: 10.1016/j.bbalip.2019.158523
|
| 99 |
Manuela Vitulo, Elisa Gnodi, Giulia Rosini, Raffaella Meneveri, Roberto Giovannoni, Donatella Barisani. Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD. International Journal of Molecular Sciences 2023; 24(16): 12748 doi: 10.3390/ijms241612748
|
| 100 |
Nikolaos Perakakis, Konstantinos Stefanakis, Michael Feigh, Sanne S. Veidal, Christos S. Mantzoros. Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non‐alcoholic steatohepatitis. Liver International 2021; 41(8): 1853 doi: 10.1111/liv.14888
|
| 101 |
Helene M. Ægidius, Sanne S. Veidal, Michael Feigh, Philip Hallenborg, Michele Puglia, Tune H. Pers, Niels Vrang, Jacob Jelsing, Birgitte R. Kornum, Blagoy Blagoev, Kristoffer T. G. Rigbolt. Multi-omics characterization of a diet-induced obese model of non-alcoholic steatohepatitis. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-58059-7
|
| 102 |
Ivan Linares, Matyas Hamar, Nazia Selzner, Markus Selzner. Steatosis in Liver Transplantation: Current Limitations and Future Strategies. Transplantation 2019; 103(1): 78 doi: 10.1097/TP.0000000000002466
|
| 103 |
Hyun-Ji Kim, Eun Bok Baek, Ji-Hee Hwang, Minyoung Lim, Won Hoon Jung, Myung Ae Bae, Hwa-Young Son, Jae-Woo Cho. Application of convolutional neural network for analyzing hepatic fibrosis in mice. Journal of Toxicologic Pathology 2023; 36(1): 21 doi: 10.1293/tox.2022-0066
|
| 104 |
Gao Sun, Charles V. Jackson, Karen Zimmerman, Li-Kun Zhang, Courtney M. Finnearty, George E. Sandusky, Guodong Zhang, Richard G. Peterson, Yi-Xin (Jim) Wang. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose. BMC Gastroenterology 2019; 19(1) doi: 10.1186/s12876-019-0958-4
|
| 105 |
Aimo Kannt, Paulus Wohlfart, Andreas Nygaard Madsen, Sanne Skovgård Veidal, Michael Feigh, Dieter Schmoll. Activation of thyroid hormone receptor‐β improved disease activity and metabolism independent of body weight in a mouse model of non‐alcoholic steatohepatitis and fibrosis. British Journal of Pharmacology 2021; 178(12): 2412 doi: 10.1111/bph.15427
|